TP53 and atrial fibrillation: In contrast, we did not see significant changes in AF of age-related CH gene mutations (e.g., DNMT3A) in either treatment arm, suggesting selective expansion of TP53-mutant clones under lenalidomide (Supplementary Fig. 2A, B).